MyOme
PrivateLast Round
VC Round
Dec 11, 2025
Est. Valuation
$132M
Total Funding Raised
$36.4M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
MyOme is a biotechnology company that offers gene analytics technology to assess the impact of DNA on health and well-being through genome sequencing, helping families understand and mitigate the risk of hereditary diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Healthcare Analytics, Patient Engagement
Business Model
B2B2C
Customer Profile
Services & Consulting, Usage-Based SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MyOme Comparables
Compare MyOme with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Variantyx | 79% | |
| Nucleus Genomics | 79% | |
| Genomic Prediction | 70% |
MyOme Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 11, 2025 | ||||
| Series B | Jun 21, 2022 | ||||
| Series A | Oct 23, 2019 | ||||
| Seed | Jul 17, 2019 |
MyOme Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Founders Fund | Series B |
| SoftBank Group | Series B |
| Norwest Venture Partners | Series A, Series B, Seed |
| Sequoia Capital | Series B, VC Round |
| Foresite Capital | Series B |
| SoftBank Corp | Series B |
| HOF Capital | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Dr. Ravi Thadhani joins the Board of Directors.
- Apr 21, 2026
Sam Roosz appointed to the Board of Directors.
MyOme Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about MyOme's valuation, stock price, and market status.
Is MyOme a public or private company?
MyOme is a private company.
What is the current stock price of MyOme?
MyOme is a private company with no public stock price. No recent secondary market data is available.
How much is MyOme worth (valuation)?
MyOme's valuation is estimated at $132.0M based on funding round data.
Can I buy MyOme stock?
MyOme shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was MyOme's last funding round?
MyOme's most recent funding round was Series B on June 21, 2022.
Who are the main investors in MyOme?
Key investors in MyOme include Norwest Venture Partners, Healthcare Venture Partners.
Will MyOme IPO soon?
No public IPO plans have been announced for MyOme.
How can I track MyOme secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor MyOme's secondary market activity and sign up for updates.